Phenylsulfonylfuroxan NO-donor phenols: Synthesis and multifunctional activities evaluation

Xie, Yundong; Yang, Yajie; Li, Sen; Yan, Xu; Lu, Wen-Fang; Chen, Zizhang; Yang, Guangde; Li, Yiping; Cao, Ricardo; Bian, Xiaoli

doi:10.1016/j.bmc.2017.06.023

Cited by 7 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phenylfuroxans 17a and 19a were not as potent as the control aminoguanidine, with IC 50 values of 3.259 mM and 3.037 mM, respectively. Moreover, hybrids 26, 27, 28, and 29 did not show any activity [50,51].…”

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 88%

“…All phenylsulfonylfuroxan compounds were more potent than aspirin (5.96% inhibition at 1.5 µM), used as control. Hybrid 20a showed the highest inhibition of 73.54% at 1.5 µM, followed by hybrids 18a, 26, and 27, with an inhibition of 65.53%, 58.14%, and 56.44% at 1.5 µM, respectively [50]. Phenylfuroxans 17a, 19a, 28, and 29 did not present higher activity than aspirin (28.11% at 0.15 mM), with 9.46%, 17.66%, 10.78%, and 12.66% inhibition at 0.15 mM, respectively [51].…”

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 93%

“…In vitro evaluation of phenylsulfonyl hybrids 18a, 20a, 26, and 27 against yeast a-glucosidase from Saccharomyces cerevisiae showed that hybrid 20a (IC50 = 187.34 μM) was more potent than acarbose (IC50 = 232.41 μM). Hybrids 18a and 26 were comparable to acarbose, with IC50 values of 263.47 μM and 278.54 μM, respectively, while hybrid 27 presented an increased IC50 value [50].…”

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 94%

“…Xie et al combined cinnamic acids with NO donor groups as a therapeutic approach against metabolic syndrome [50] and diabetes mellitus [51]. In particular, phenylsulfonyland phenylfuroxan alcohols were linked with some natural cinnamic acid derivatives (Figures 7 and 9).…”

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 99%

“…In particular, phenylsulfonyland phenylfuroxan alcohols were linked with some natural cinnamic acid derivatives (Figures 7 and 9). In vitro evaluation of phenylsulfonyl hybrids 18a, 20a, 26, and 27 against yeast a-glucosidase from Saccharomyces cerevisiae showed that hybrid 20a (IC 50 In vitro evaluation of phenylfuroxan hybrids 17a, 19a, 28, and 29 against a-glucosidase (maltase and sucrase) from rat small intestine showed that only hybrids 17a (IC50 = 301.73 μM in maltase and 223.36 μM in sucrase) and 19a (IC50 = 123.36 μM in maltase and 155.03 μM in sucrase) exhibited any activity. None of the hybrids presented better inhibitory activity than acarbose (5.59 μM in maltase and 2.31 μM in sucrase), and hybrids 28 and 29 did not show any activity [51].…”

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 99%

See 4 more Smart Citations

Hybrids as NO Donors

Tsopka

Hadjipavlou‐Litina

2021

IJMS

View full text Add to dashboard Cite

Cinnamic acid and its derivatives have been studied for a variety of biological properties, including anti-inflammatory, antioxidant, anticancer, antihypertensive, and antibacterial. Many hybrids of cinnamic derivatives with other bioactive molecules have been synthesized and evaluated as nitric oxide (NO) donors. Since NO plays a significant role in various biological processes, including vasodilation, inflammation, and neurotransmission, NO donor groups are incorporated into the structures of already-known bioactive molecules to enhance their biological properties. In this review, we present cinnamic hybrids with NO-donating ability useful in the treatment of several diseases.

show abstract

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 88%

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 93%

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 94%

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 99%

Section: Furoxan Hybrids As Antidiabetic Agentsmentioning

confidence: 99%

See 3 more Smart Citations

Hybrids as NO Donors

Tsopka

Hadjipavlou‐Litina

2021

IJMS

View full text Add to dashboard Cite

show abstract

Synthesis and evaluation of new sesamol-based phenolic acid derivatives with hypolipidemic, antioxidant, and hepatoprotective effects

et al. 2021

Self Cite

View full text Add to dashboard Cite

The objective of this study is to synthesize a series of sesamol-based phenolic acid derivatives, which were designed by combination principle. The hypolipidemic activity of all these compounds was preliminarily screened by acute hyperlipidemic mice model induced by Triton WR 1339, in which compound T6 exhibited more significant reducing plasma TG and TC than fenofibrate. Compound T6 was also found to obviously decrease TG and TC both in the plasma and hepatic tissue of high-fat-dietinduced hyperlipidemic mice. Moreover, T6 showed hepatoprotective effects, which remarkable amelioration in characteristic liver enzymes was examined and the histopathological observation displayed that compound T6 inhibited lipids accumulation in the hepatic. The levels of PPAR-α receptor related to lipids metabolism in hepatic tissue were upregulated after T6 treatment. Other potent effects of T6 such as antioxidant and anti-inflammatory activity were also observed. On the bases of these findings, compound T6 may serve as an effective hypolipidemic and hepatoprotective agent.

show abstract